SCHEMBL7175261

SCHEMBL7175261

CCCCCP(=O)(C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.44
PLK3 Q9H4B4 1/20 0.44
CETP P11597 6/20 0.40
EPHX2 P34913 1/20 0.39
F2R P25116 1/20 0.39
TSHR P16473 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
CNR2 P34972 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7179997 0.99 PLK1 (0.46) PLK1PLK3CETPEPHX2F2R
SCHEMBL7181345 0.99 PLK1 (0.46) PLK1PLK3CETPEPHX2F2R
SCHEMBL7175556 0.99 PLK1 (0.46) PLK1PLK3CETPEPHX2F2R
SCHEMBL7175537 0.99 PLK1 (0.46) PLK1PLK3CETPEPHX2F2R
SCHEMBL7175909 0.96 PLK1 (0.42) PLK1PLK3CETPEPHX2F2R
SCHEMBL7184553 0.91 F2R (0.41) PLK1PLK3EPHX2F2RTSHR
SCHEMBL27561240 0.86 CETP (0.42) PLK1PLK3CETPEPHX2F2R
SCHEMBL27485665 0.86 CETP (0.42) PLK1PLK3CETPEPHX2F2R
SCHEMBL27500286 0.86 CETP (0.42) PLK1PLK3CETPEPHX2F2R
SCHEMBL7187317 0.85 GAA (0.41) PLK1PLK3EPHX2F2RTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 PLK1 2655/4885PLK3 731/4885CETP 750/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 PLK1 2774/4885PLK3 842/4885CETP 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.